3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
6
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Small Cell Lung Carcinoma
1
Neoplasm Metastasis
1
Melanoma
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Neuroendocrine
1
Interventions
pembrolizumab
15
Nivolumab
10
avelumab
9
atezolizumab
8
Gemcitabine
8
Cisplatin
8
Magnetic Resonance Spectroscopy
6
durvalumab
5
Specimen Handling
5
Docetaxel
5
Carboplatin
5
Paclitaxel
4
Ipilimumab
4
tislelizumab
3
sacituzumab govitecan
3
enfortumab vedotin
3
Taxes
3
Pemetrexed
3
Mitomycin
3
eribulin
2
erdafitinib
2
cabozantinib
2
Doxorubicin
2
CTLA-4 Antigen
2
ALT-803
2
zimberelimab
1
veliparib
1
urelumab
1
tazemetostat
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma, Transitional Cell
×
budigalimab
×
Clear all
NCT06632951
2025-08-11
LIVIGNO-3
AbbVie
Phase 2
Active not recruiting
150 enrolled